论文部分内容阅读
将64例口服降糖药T_2DM患者,随机分为实验组(31例);对照组(33例);正常组(32例)。实验组均加服罗格列酮(4mg/日),疗程6个月;分别测量T_2DM实验组、T_2DM对照组治疗前后及正常对照组骨密度(BMD)并进行比较。结果:T_2DM患者BMD低于正常对照组(P<0.05);实验组治疗后髋部及腰椎BMD均有所下降(0.90±0.17:0.77±0.15;1.02±0.19:0.82±0.08,P<0.05),对照组治疗前后髋部及腰椎BMD无显著变化(1.00±0.05:1.10±0.02;1.08±0.05:1.07±0.06,P>0.05)。结论:罗格列酮可致T_2DM骨密度降低,T_2DM在应用此类药物时有潜在的发生骨质疏松性骨折的风险。
Sixty-two oral hypoglycemic agents, T2DM, were randomly divided into experimental group (31 cases), control group (33 cases) and normal group (32 cases). The experimental group were given rosiglitazone (4mg / day) for 6 months. The BMD of T 2 DM group and T 2 DM group before and after treatment and normal control group were measured and compared. Results: The BMD of T 2DM patients was lower than that of the normal control group (P <0.05). The BMD of the hip and lumbar spine of the experimental group decreased after treatment (0.90 ± 0.17: 0.77 ± 0.15; 1.02 ± 0.19: 0.82 ± 0.08, P <0.05) There was no significant change in BMD of the hip and lumbar spine before and after treatment in the control group (1.00 ± 0.05 vs 1.10 ± 0.02; 1.08 ± 0.05: 1.07 ± 0.06, P> 0.05). CONCLUSION: Rosiglitazone can reduce the bone mineral density of T 2 DM, and T 2 DM is potentially at risk of osteoporotic fractures when used with these drugs.